中文
EN
News Center
News Center
Dr. Keene Wei, President of Viwit, Invited to Speak at the 2026 In Vivo Cell Therapy Innovation Summit
Author：
VIWIT
Release Time：
2026-02-28
Since the landmark breakthrough of CAR-T therapy in hematologic malignancies, cellular immunotherapy has become a central focus of the global medical community. However, traditional ex vivo CAR-T therapy is hindered by complex manufacturing processes, high costs, and lengthy preparation times—factors that significantly limit its clinical application and patient accessibility. In recent years, in vivo CAR-T technology, which enables the direct "reprogramming" of T cells inside the patient’s body using advanced gene delivery systems, has emerged as a transformative approach and a core direction for the next generation of cell therapy.
To bring together global expertise and explore both technological breakthroughs and industrialization pathways in in vivo cell therapy, the 2026 In Vivo Cell Therapy Innovation Summit will be held in Suzhou in 2026. The summit will focus on key topics including LNP and viral vector technologies, targeted delivery efficiency, preclinical models, quality control, and large-scale manufacturing. It aims to establish a dynamic platform for in-depth exchange among industry, academia, research institutions, and medical professionals.
Viwit Pioneers Targeted Delivery; Dr. Keene Wei to Deliver Keynote Presentation
As an innovative leader in the field of nucleic acid drug delivery in China, Viwit is committed to expanding the boundaries of genetic medicine. Dr. Keene Wei, President of Viwit, has been invited to attend the summit and will deliver a keynote presentation titled "Targeted Lipid Nanoparticle Platform Technology," sharing Viwit’s latest advancements in targeted LNP with global experts.
Core Advantages of Viwit’s Targeted LNP Platform
Lipid nanoparticles have become a validated delivery system for genetic medicines. However, their application has traditionally been limited largely to hepatocytes and vaccine development. To overcome this limitation, Viwit has developed a proprietary targeted lipid nanoparticle platform with independent intellectual property rights.
This platform integrates unique MAP (Microprotein Architecture Platform) capabilities with novel proprietary ionizable lipids to engineer LNPs capable of actively targeting specific extrahepatic cell types and tissues. This targeted strategy opens new avenues for developing advanced therapeutic modalities. Current R&D efforts are primarily focused on the following areas:
·tLNP-mRNA: For in vivo generation of CAR therapies.
·tLNP-siRNA: For treating genetically defined diseases beyond the liver.
Collaborating to Shape the Future of In Vivo Cell Therapy
Dr. Keene Wei commented: "We look forward to engaging in meaningful discussions with global peers at this summit, working together to advance in vivo cell therapy from concept to clinical application and from the laboratory to industrial reality."
The 2026 In Vivo Cell Therapy Innovation Summit is not only an academic highlight but also a profound convergence of innovation and industry. We sincerely invite you to join us on-site to explore the future of in vivo cell therapy alongside Dr. Keene Wei and other industry leaders.